SNP (Single Nucleotide Polymorphism) molecular marker for predicting hypoglycemic curative effect of dapagliflozin and application thereof

By using the SNP molecular marker at the rs1071592 locus of the AHSG gene and detecting genotypes using a Snapshot SNP genotyping kit, the problem of variability in the efficacy of dapagliflozin among different patients has been solved, realizing the genetic pharmacology basis for personalized treatment and improving treatment efficacy.

CN119020486APending Publication Date: 2024-11-26THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411436996.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The efficacy of dapagliflozin in lowering blood sugar varies significantly among different patients, making it difficult to achieve individualized treatment, and there is a lack of research on its correlation with genetic factors.

Method used

We provide the SNP molecular marker at the rs1071592 locus of the AHSG gene, and use a Snapshot SNP genotyping kit to detect different genotypes to predict the efficacy of dapagliflozin in improving insulin resistance.

Benefits of technology

This study provides a pharmacogenetic basis for individualized treatment of dapagliflozin, clarifying that mutations at the rs1071592 site of the AHSG gene affect AHSG gene expression and improve the accuracy of predicting treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020486A_ABST
    Figure CN119020486A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to an SNP (Single Nucleotide Polymorphism) molecular marker for predicting the hypoglycemic curative effect of dapagliflozin and application of the SNP molecular marker. The nucleotide sequence of the molecular marker is as shown in SEQ ID NO.1, the 144th basic group from the 5'end of the nucleotide sequence is an SNP site, M is a basic group A or a basic group C, the curative effect is the curative effect of treating the type 2 diabetes, and the SNP site of the molecular marker has three genotypes which are respectively homozygous CC, homozygous AA and heterozygous CA; the prediction is as follows: compared with a type 2 diabetes patient carrying the genotype of the molecular marker SNP site CC, the effect of dapagliflozin for improving insulin resistance is poor for the type 2 diabetes patient carrying the genotype of the molecular marker SNP site AA or CA. Results of the invention can provide experimental basis and theoretical basis for individualized treatment of dapagliflozin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a SNP molecular marker for predicting the glucose-lowering efficacy of dapagliflozin and an application thereof. Background Art

[0002] Type 2 diabetes, referred to as T2DM, is a chronic progressive disease characterized by dysregulation of glucose metabolism caused by the interaction of genetic and environmental factors. According to the latest data from the International Diabetes Federation, the number of people with diabetes worldwide is expected to reach 438 million by 2030, and T2DM is the third most common disease after cancer and cardiovascular disease. The basic characteristics of T2DM are insufficient insulin secretion from pancreatic β cells and insulin resistance IR in target tissues such as the liver, adipose tissue and skeletal muscle. IR refers to the reduced sensitivity and responsiveness of target cells to insulin, that is, the weakened ability of insulin to take up and clear glucose from peripheral tissues leads to glucose metabolism disorders. The presence of IR increases the risk of complications in patients with T2DM.

[0003] Dapagliflozin mainly achieves the purpose of lowering blood sugar by inhibiting the renal tubular SGLT2 receptor, and has a significant effect on improving IR. Studies have shown that taking dapagliflozin can reduce BMI, waist circumference, fasting blood sugar and uric acid, and increase insulin sensitivity without affecting insulin secretion. Clinical practice shows that there are obvious individual differences in dapagliflozin. Studies have found that T2DM susceptibility gene polymorphisms may affect the clinical efficacy of dapagliflozin in improving IR.

[0004] The AHSG gene is located on chromosome 3q27 and is considered to be a susceptibility site for metabolic syndrome and T2DM. More importantly, several SNP sites of AHSG have been found to be associated with adipocyte insulin-like effects, dyslipidemia, IR, T2DM, and diabetic nephropathy. However, there are no studies reporting the correlation between the AHSG gene polymorphism and dapagliflozin treatment of IR. Summary of the invention

[0005] In view of this, the technical problem to be solved by the present invention is to provide a SNP molecular marker for predicting the hypoglycemic efficacy of dapagliflozin and its application.

[0006] The present invention first provides a SNP molecular marker for predicting the hypoglycemic efficacy of dapagliflozin, wherein the SNP molecular marker comprises the rs1071592 site of the AHSG gene, the nucleotide sequence of the molecular marker is as shown in SEQ ID NO.1, and the 144th base from the 5′ end of the nucleotide sequence is the SNP site, wherein M is base A or base C.

[0007] Dapagliflozin is the first sodium-glucose cotransporter 2 inhibitor to enter the clinic, with good glucose-lowering, weight-reducing and cardiorenal protection effects. With the gradual accumulation of evidence-based medicine, the status of this type of drug in the treatment of T2DM has been continuously improved. Guidelines of many countries use SGLT2i as a single drug or a combination of multiple oral hypoglycemic drugs and basal insulin therapy when blood sugar control is ineffective. Studies have shown that the proteinuria reduction response of dapagliflozin varies significantly among different patients. In our clinical pharmacy practice, we found that some T2DM patients did not have obvious improvement in IR after receiving dapagliflozin treatment, and it was difficult to achieve the ideal blood sugar control target. A large number of clinical studies and practical experience have shown that there are individual differences in the efficacy of hypoglycemic drugs, and its mechanism is related to genetic factors, gender, age, height, weight, dietary habits, medication compliance, disease progression and other factors, among which genetic factors play a key role. Therefore, it is very necessary to study the correlation and mechanism between genetic factors and the clinical efficacy of dapagliflozin, and provide a genetic pharmacological basis and laboratory basis for the precision drug treatment of diabetes.

[0008] Fetuin A is a plasma glycoprotein synthesized and secreted by liver cells and widely present in the liver, muscle and blood. The AHSG gene is located on chromosome 3q27 and has a high degree of genetic polymorphism. It is a susceptibility site for T2DM and metabolic syndrome. The results of a case-control study showed that single nucleotide polymorphisms rs1071592, rs4917, rs4918 and rs2248690 in the promoter region of the AHSG gene were associated with T2DM and IR. In addition, cohort studies with Caucasians and yellow people as research subjects found that synonymous coding SNPs located on exon 7 of the AHSG gene, rs1071592 allele mutations, were associated with T2DM. Andersen et al. found that rs2077119 and rs2518136 were significantly associated with triglyceride indicators in patients with T2DM, while AHSG-469T>G, that is, rs2077119 gene polymorphism, was associated with insulin-mediated lipolysis inhibition. It can be seen that AHSG gene polymorphism is closely related to obesity, T2DM and IR.

[0009] Based on prospective clinical studies, the present invention searches for the SNP site of the AHSG gene that affects the IR-improving effect of dapagliflozin, clarifies that rs1071592 of the AHSG gene is a key factor affecting the clinical efficacy of dapagliflozin, and further confirms that the allele mutation of the rs1071592 site affects the expression of the AHSG gene.

[0010] Therefore, the present invention also provides the use of the detection reagent of the SNP molecular marker in the preparation of a product for predicting the efficacy of dapagliflozin.

[0011] Furthermore, the therapeutic effect is the efficacy of dapagliflozin in improving insulin resistance in diabetic patients.

[0012] Furthermore, the diabetes is type 2 diabetes.

[0013] Furthermore, the molecular marker SNP site has three genotypes, namely homozygous CC, homozygous AA and heterozygous CA;

[0014] The prediction package is: compared with type 2 diabetes patients carrying the AA or CA genotype of the molecular marker SNP site, the effect of dapagliflozin on improving insulin resistance is poorer in type 2 diabetes patients carrying the CC genotype of the molecular marker SNP site.

[0015] Furthermore, the product is a Snapshot SNP typing kit.

[0016] Furthermore, the kit contains specific amplification primers and extension primers for the SNP molecular marker.

[0017] Furthermore, the sequences of the specific amplification primer and the extension primer are shown in SEQ ID NOs. 2 to 4, respectively.

[0018] The present invention has the following beneficial effects:

[0019] The present invention first discovered that the mutation of the rs1071592 site of the AHSG gene is associated with the risk of T2DM; dapagliflozin can improve blood sugar, blood lipids and IR in patients with T2DM; in patients with T2DM, the results of multiple linear regression analysis showed that the rs1071592 site of the AHSG gene was associated with the efficacy of dapagliflozin in improving IR; the mutation of the rs1071592 site of the AHSG gene can affect the expression level of plasma AHSG protein in patients with T2DM. The results of the present invention can provide an experimental basis and theoretical basis for the individualized treatment of dapagliflozin. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Comparison chart of clinical indicators of patients with different genotypes before and after 3 months of continuous treatment with dapagliflozin, among which A is the HbA1c comparison chart, B is the TC comparison chart, C is the LDL-C comparison chart, and D is the HOMA-I comparison chart; mean ± standard deviation, n = 116. Compared with the CC genotype, ** P < 0.01; *** P<0.001.

[0021] Figure 2The comparison chart of clinical index differences of patients with different genotypes before and after 3 months of continuous treatment with dapagliflozin, among which A is the HbA1c difference comparison chart, B is the TC difference comparison chart, C is the LDL-C difference comparison chart, and D is the HOMA-I difference comparison chart; mean ± standard deviation, n = 116. Compared with the CC genotype, * P<0.05, ** P<0.01.

[0022] Figure 3 Comparison of plasma AHSG protein expression among different genotypes of AHSG gene rs1071592. Mean ± SD, n = 116. Compared with CC genotype, *** P<0.001. DETAILED DESCRIPTION

[0023] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0024] The following examples involve nouns, English counterparts and abbreviations:

[0025] Type 2 diabetes mellitus: type 2diabetes mellitus, T2DM.

[0026] Body Mass Index: Body Mass Index, BMI.

[0027] Fasting insulin level: Fast Insulin, FINS.

[0028] Fasting plasma glucose: fasting plasma glucose, FPG.

[0029] Insulin resistance: insulin resistance, IR.

[0030] Fetuin A: α2-heremans-schmid glycoprotein, AHSG.

[0031] Triglyceride: triglyceride, TG.

[0032] Waist to hip ratio: waist to hip ratio, WHR.

[0033] Blood sugar: postprandial plasma glucose, PPG

[0034] Cholesterol: total cholesterol, TC.

[0035] High-density lipoprotein: high-density lipoprotein-cholesterol, HDL-C.

[0036] Low-density lipoprotein: low-density lipoprotein-cholesterol, LDL-C.

[0037] IR index: Homeostasis model assessment for insulin resistance, HOMA-IR.

[0038] Insulin secretion index: Homeostasis model assessment for beta cell function, HOMA-β.

[0039] Mean ± SD: Mean ± SD.

[0040] One-way ANOVA: one-way ANOVA.

[0041] Hardy-Weinberg: Hardy-weinberg.

[0042] The present invention provides a SNP molecular marker for predicting the glucose-lowering efficacy of dapagliflozin, the nucleotide sequence of the molecular marker is shown in SEQ ID NO.1, and the 144th base from the 5′ end of the nucleotide sequence is a SNP site, wherein M is base A or base C.

[0043] SEQ ID NO.1: 5′-GAGGAAATTGGGTGCCAGTGCCACCTGGGCCTGTG GGTTGTCTTGCCTGGGAGGAGGAAGCAAACTAACTGAAGGAAATGGTCCTTTTTCCAGCCCGTGAGCTCACAGCCCCAACCAGAAGGTGCCAATGAAGCAGTCCCCACMCCCGTGGTGGACCCAGATGCACCTCCGTCCCCTCCACT TGGCGCACCTGGACTCCCTCCAGCTGGCTCACCCCCAGACTCCCATGTGTTACTGGCAGCTCCTCCAGGACACCAGTTGCACCGGGCGCACTACGACCTGCGCCACACCTTCATGGGTGTGGTCTCATTGGGGTCACCCTCAG-3′.

[0044] Example 1

[0045] 1. Methods

[0046] 1.1 Research subjects

[0047] Peripheral blood samples from T2DM patients and healthy controls who met the criteria were collected in the Department of Endocrinology and Physical Examination Center of the Affiliated Hospital of Xuzhou Medical University. This study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University, approval number: XYFY2021-KL094-01, and all subjects signed informed consent before the clinical trial.

[0048] T2DM group:

[0049] Inclusion criteria: (1) meeting the diagnostic criteria for T2DM established by the WHO; (2) being Han residents in Xuzhou; (3) aged 20 years or older and 75 years or younger; (4) having HbA1c>7.0%.

[0050] Exclusion criteria: (1) type 1 diabetes or other special types of diabetes; (2) currently experiencing or having experienced acute complications of diabetes in the past 2 weeks; (3) having experienced acute cardiovascular and cerebrovascular events in the past 3 months; (4) having obvious abnormalities in liver and kidney function, or having severe liver and kidney diseases; (5) having urinary stones or infections; (6) planning to become pregnant, or being pregnant or breastfeeding; (7) having recently taken uric acid-lowering drugs, weight-loss drugs, or other drugs that interfere with clinical indicators.

[0051] Healthy control group:

[0052] Inclusion criteria: (1) Han residents in Xuzhou area; (2) FPG < 7.0 mmol / L; (3) HbA1c < 6.2%; (4) aged 20 years or older and less than 75 years old.

[0053] Exclusion criteria: (1) endocrine and metabolic diseases, cardiovascular diseases, liver and kidney dysfunction, etc.; (2) patients currently taking other preventive and therapeutic drugs; (3) patients with blood relationship with the enrolled subjects; (4) patients planning to become pregnant, or patients in the pregnancy or lactation period.

[0054] Dapagliflozin treatment group:

[0055] Inclusion criteria: (1) newly diagnosed T2DM patients without drug treatment; (2) Han residents in Xuzhou; (3) aged 20 years or older and 75 years or younger; (4) HbA1c>7.0%; (5) BMI between 20 and 35 kg / m 2 (6) Continuous use of dapagliflozin for more than 3 months.

[0056] Exclusion criteria: (1) type 1 diabetes or other special types of diabetes; (2) currently experiencing or having experienced acute complications of diabetes in the past 2 weeks; (3) having experienced acute cardiovascular and cerebrovascular events in the past 3 months; (4) having obvious abnormalities in liver and kidney function, or having severe liver and kidney diseases; (5) having urinary stones or infections; (6) planning to become pregnant, or being pregnant or breastfeeding; (7) having recently taken uric acid-lowering drugs, weight-loss drugs, or other drugs that interfere with clinical indicators.

[0057] 1.2 Clinical trial plan

[0058] 1.2.1 Collect the patient's general information: including name, gender, age, place of residence, contact number, height, weight, waist circumference, hip circumference, blood pressure, etc. Calculate waist-to-hip ratio and BMI, BMI = weight (kg) / height (m) 2 .

[0059] 1.2.2 Dapagliflozin treatment plan: T2DM patients take dapagliflozin tablets orally before meals, trade name: Andatang, AstraZeneca Pharmaceuticals Co., Ltd., 10 mg / d, for more than 3 months. During the treatment, the patient's diet and exercise habits remain unchanged, the dosage of antihypertensive and lipid-lowering drugs remains unchanged, and various indicators before and after medication are tested.

[0060] 1.2.3 Blood sampling: The subjects were fasting for more than 8 hours, and fasting venous blood was collected from the antecubital cavity to measure blood sugar, insulin, blood lipids and HbA1c. After the patients ate 100 grams of sugar-free steamed bread, venous blood was collected 120 minutes later to measure blood sugar and insulin. The blood sugar and insulin were measured once before drug treatment and once after 3 months of treatment.

[0061] 1.2.4 Clinical observation indicators and measurement methods

[0062] 1.2.4.1 Physiological and biochemical indicators include: FPG, 2h postprandial blood glucose, fasting C-peptide, postprandial C-peptide, HbA1c, FINS, PINS, TC, TG, HDL-C, LDL-C. Calculate HOMA-IR and HOMA-β. HOMA-IR = FINS (mU / L) * FPG (mmol / L) / 22.5, HOMA-β = 20 * FINS / (FPG-3.5).

[0063] Determination method: blood glucose was determined by glucose oxidase method; TC, TG, HDL-C, and LDL-C were determined by semi-automatic biochemical analyzer; insulin was determined by electrochemiluminescence method; and HbA1c was determined by high pressure liquid chromatography.

[0064] 1.3 Extraction of genomic DNA from peripheral blood samples

[0065] Extract DNA using a DNA extraction kit according to the instructions.

[0066] 1.4 Genotyping

[0067] Tianhao Bio was commissioned to use the Snapshot method for genotyping. The raw data were collected and genotyping was performed on the GeneMapper4.1 analysis ABI3730XL sequencer. The primer sequences used in the Snapshot method are as follows:

[0068] Upstream primer: 5′-CTCCTTTAACCCACGGTCACG-3′, shown in SEQ ID NO.2.

[0069] Downstream primer: 5′-CTGAGGGTGACCCCAATGAGAC-3′, shown in SEQ ID NO.3.

[0070] Extension primer: 5′-TTTTTTTTTTTTTTTTTTTTTTTTTCCAATGAAGCAGTC CCCAC-3′, shown in SEQ ID NO.4.

[0071] 1.5 Determination of plasma AHSG protein level

[0072] According to the instructions, the ELISA method was used to determine the AHSG protein content in the plasma of T2DM patients with different AHSG genotypes.

[0073] 1.6 Data processing and statistical analysis

[0074] Data were processed using SPSS 21.0 statistical software, and chi-square tests were used to test whether the count data and genotype distribution conformed to Hardy-Weinberg equilibrium. Measurement data were expressed as mean ± standard deviation. Paired t-tests were used to compare parameters between the two groups before and after treatment. For normally distributed parameters, independent sample t-tests were used for comparison between the two groups, one-way analysis of variance was used for comparison between multiple groups, and non-parametric tests were used for skewed distribution parameters. Multiple linear regression methods were used to analyze the correlation between dapagliflozin's effect on improving IR and the AHSG gene locus. The hypothesis test level was determined at α = 0.05. P < 0.05 indicated that the difference was statistically significant.

[0075] 2. Results

[0076] 2.1 Comparison of clinical data between healthy controls and T2DM patients

[0077] A total of 217 healthy controls and 243 T2DM patients were included in this study. Statistical analysis showed that there was no significant difference between the two groups in terms of gender, age and HDL-C. Compared with the healthy control group, the BMI, WHR, FPG, HbA1c, TC, TG and LDL-C levels in the T2DM group were significantly increased, as shown in Table 1.

[0078] Table 1: Comparison of clinical indicators between 217 healthy controls and 243 T2DM patients

[0079]

[0080]

[0081] 2.2 Balance test analysis

[0082] This study included 576 subjects who met the inclusion and exclusion criteria, including 217 healthy subjects, 243 T2DM patients and 116 patients in the dapagliflozin group. The Hardy-Weinberg equilibrium test was performed on the six SNPs sites of the AHSG gene to evaluate the population representativeness of the sample. The six SNPs sites of the three groups of subjects were in Hardy-Weinberg equilibrium, as shown in Tables 2, 3 and 4, indicating that the samples were representative of the population.

[0083] Table 2: Hardy-Weinberg equilibrium test and frequency of each gene locus in the healthy control group, n = 217

[0084]

[0085]

[0086] Note: “-” means there is no data for this item.

[0087] Table 3: Hardy-Weinberg equilibrium test and frequency of each gene locus in T2DM group, n=243

[0088]

[0089] Note: “-” means there is no data for this item.

[0090] Table 4: Hardy-Weinberg equilibrium test and frequency of each gene locus in the dapagliflozin group, n=116

[0091]

[0092]

[0093] Note: “-” means there is no data for this item.

[0094] 2.3 Distribution of gene polymorphisms in healthy controls and T2DM patients

[0095] The genotype and allele frequency distribution of the AHSG gene polymorphism sites in the healthy control group and the T2DM group are shown in Table 5. In the healthy control group, there were 18 patients with AA genotype at the rs1071592 site of the AHSG gene, 77 patients with CA genotype, and 122 patients with CC genotype, with frequencies of 8.30%, 35.48%, and 56.22%, respectively, with A allele frequencies of 26.04% and C allele frequencies of 73.96%. In the T2DM group, there were 6 patients with AA genotype at the rs1071592 site of the AHSG gene, 78 patients with CA genotype, and 159 patients with CC genotype, with frequencies of 2.47%, 32.10%, and 65.43%, respectively, with A allele frequencies of 18.52% and C allele frequencies of 81.48%. There were statistically significant differences in the distribution of genotypes and allele frequencies at the rs1071592 locus of the AHSG gene between Han T2DM patients and healthy controls in Xuzhou, China.

[0096] In the healthy control group, there were 94 patients with CC genotype, 92 patients with CT genotype, and 31 patients with TT genotype at the rs4917 locus of AHSG gene, with frequencies of 43.31%, 42.40%, and 14.29%, respectively. The C allele frequency was 64.52%, and the T allele frequency was 34.48%. In the T2DM group, there were 118 patients with CC genotype, 110 patients with CT genotype, and 15 patients with TT genotype at the rs4917 locus of AHSG gene, with frequencies of 48.56%, 45.27%, and 6.17%, respectively. The C allele frequency was 71.19%, and the T allele frequency was 28.81%. The distribution of genotypes and allele frequencies at the rs4917 locus of AHSG gene in Han T2DM patients and healthy controls in Xuzhou, China was statistically significant.

[0097] There was no significant difference in the distribution of genotype and allele frequencies of AHSG gene rs2518136, rs2077119, rs2518136, and rs4831 loci between Han T2DM patients and healthy controls in Xuzhou, China, P>0.05.

[0098] Table 5: The frequencies of different genotypes and alleles in 217 healthy controls and 243 T2DM patients

[0099] distributed

[0100]

[0101] Note: “-” means there is no data for this item.

[0102] 2.4 Comparison of clinical indicators of T2DM patients before and after dapagliflozin treatment

[0103] In order to observe the efficacy of dapagliflozin on patients with T2DM, this study included 116 newly diagnosed patients with T2DM who used dapagliflozin for 3 consecutive months. Statistical analysis of the clinical indicators of T2DM patients before and after medication showed that there was no significant change in the patients' BMI, HOMA-β, and HDL-C levels. Compared with the clinical indicators before dapagliflozin treatment, the HOMA-IR, FPG, HbA1c, TC, TG, and LDL-C levels of patients after 3 months of continuous treatment with dapagliflozin were significantly reduced, and the difference was statistically significant, as shown in Table 6.

[0104] Table 6: Differences in clinical indicators of T2DM patients before and after 3 months of continuous treatment with dapagliflozin, n=116

[0105] index Before treatment After treatment P-value <![CDATA[BMI,kg / m 2 ]]> 26.42±0.34 26.37±0.35 0.915 HOMA-β 90.10±28.38 73.79±9.57 0.568 HOMA-IR 11.07±1.60 4.73±0.48 0.002 FPG, mmol / L 9.16±0.28 8.64±0.26 0.047 HbA1c, % 8.89±0.16 8.21±0.14 0.034 TC, mmol / L 5.01±0.18 4.39±0.11 0.018 TG, mmol / L 2.62±0.23 1.96±0.19 0.032 HDL-C, mmol / L 1.01±0.03 1.14±0.12 0.269 LDL-C, mmol / L 2.96±0.11 2.38±0.09 0.048

[0106] 2.5 Effect of genetic polymorphism on the efficacy of dapagliflozin

[0107] In a case-control study, we found that the genotype and allele frequency distribution of the AHSG gene rs1071592 and rs4917 sites were different in the T2DM group and the healthy control group. To further observe the effect of AHSG gene polymorphism on the efficacy of dapagliflozin, we collected 116 T2DM patients who had been using dapagliflozin for 3 consecutive months and observed the clinical data before and after 3 months of dapagliflozin treatment. Since the number of patients with homozygous mutations at the AHSG gene rs1071592 and rs4917 sites was small, the heterozygous and homozygous mutation genotypes were combined and analyzed using the allele dominant model.

[0108] There were 66 patients with CC genotype at rs1071592 of AHSG gene, including 39 males and 27 females, and 50 patients with CA and AA genotypes, including 29 males and 21 females. Comparing the clinical indicators of patients with CC, CA, and AA genotypes, there was no statistical difference in gender and age among patients with different genotypes. Before treatment with dapagliflozin, there was no significant difference in the physiological and biochemical indicators of patients with different genotypes; after 3 months of continuous treatment with dapagliflozin, the levels of HbA1c, TC, LDL-C, and HOMA-IR in patients with CC genotype were significantly higher than those in patients with CA and AA genotypes, and the difference was statistically significant, as shown in Table 7. Figure 1 Further comparison of the differences in the main clinical indicators of T2DM patients before and after dapagliflozin treatment showed that the decreases in HbA1c, TC, LDL-C, and HOMA-IR in patients with CC genotype at the rs1071592 locus of the AHSG gene were significantly lower than those in patients with CA and AA genotypes, and the differences were statistically significant. Figure 2The above results show that the improvement effect of HOMA-IR, HbA1c, TC, and LDL-C in T2DM patients with CC genotype at AHSG gene rs1071592 site is significantly better than that in T2DM patients with CA genotype at AHSG gene rs1071592 site.

[0109] There were 54 patients with CC genotype at rs4917 of AHSG gene, including 31 males and 23 females, and 62 patients with CT and TT genotypes, including 32 males and 30 females. Comparing the clinical indicators of patients with CC, CT, and TT genotypes, there were no significant differences in the physiological and biochemical indicators of patients with different genotypes before and after treatment with dapagliflozin, as shown in Table 7.

[0110] Table 7: Differences in clinical indicators of 116 T2DM patients between different genotypes of AHSG gene rs1071592 and rs4917 before and after 3 months of continuous treatment with dapagliflozin

[0111]

[0112] In the table: “Before” means 3 months before treatment; “After” means 3 months after treatment.

[0113] 2.6 Correlation analysis of dapagliflozin improving HOMA-IR

[0114] To further determine the correlation between AHSG gene polymorphism and HOMA-IR improvement after dapagliflozin treatment, we used multiple linear regression analysis, with the decrease in HOMA-IR after 3 months of dapagliflozin treatment as the dependent variable, and age, gender, BMI, FPG, HbA1c, TC, TG, HDL-C, LDL-C, baseline HOMA-IR, rs4917 and rs1071592 as independent variables. The results showed that baseline HOMA-IR and rs1071592 were significantly correlated with dapagliflozin to improve HOMA-IR, as shown in Table 8.

[0115] Table 8: Multiple linear regression analysis of HOMA-IR improvement after 3 months of dapagliflozin treatment, n=116

[0116] index β 95% CI P-value Age, years old -0.014 (-0.131,0.104) 0.817 Gender, male / female 1.885 (-0.843,4.613) 0.172 <![CDATA[BMI,kg / m 2 ]]> 0.133 (-0.221,0.487) 0.455 FPG, mmol / L 0.294 (-0.201,0.790) 0.240 HbA1c, % -0.540 (-1.273,0.193) 0.146 TC, mmol / L 0.110 (-2.503,2.723) 0.933 TG, mmol / L -0.082 (-1.489,1.325) 0.908 HDL-C, mmol / L 1.294 (-4.541,7.130) 0.659 LDL-C, mmol / L 0.558 (-2.395,3.511) 0.707 BaselineHOMA-IR 1.017 (0.944,1.090) <0.001 rs4917 0.001 (-0.002,0.004) 0.565 rs1071592 4.254 (1.051,5.820) 0.001

[0117] 2.7 Effect of gene polymorphism on AHSG protein expression.

[0118] Through prospective clinical studies, we first found that AHSG risk gene mutations were associated with the efficacy of dapagliflozin. Multiple linear regression analysis further found that the rs1071592 site of the AHSG gene affected the efficacy of dapagliflozin through HOMA-IR.

[0119] To study the role of rs1071592 in the liver and its molecular mechanism of affecting the efficacy of dapagliflozin, we indirectly measured the expression of AHSG protein in the patient's plasma. Plasma was collected from 116 patients with T2DM, and the ELISA method was used to detect the plasma AHSG protein content in patients with different genotypes of the AHSG gene rs1071592 locus, to further explore the effect of AHSG gene polymorphism on AHSG protein expression. Figure 3 As shown, the expression of plasma AHSG protein in patients with CC genotype was significantly higher than that in patients with CA+AA genotype.

[0120] Although preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they are aware of the basic inventive concepts. The present invention is intended to include these changes and modifications if they fall within the scope of the claims and their equivalents.

Claims

1. SNP molecular markers for predicting the hypoglycemic efficacy of dapagliflozin, It is characterized in that The nucleotide sequence of the molecular marker is shown in SEQ ID NO.1, and the 144th base from the 5′ end of the nucleotide sequence is a SNP site, wherein M is base A or base C.

2. Use of the SNP molecular marker detection reagent according to claim 1 in the preparation of a product for predicting the efficacy of dapagliflozin.

3. Use of the SNP molecular marker detection reagent according to claim 2 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The therapeutic effect is the efficacy of dapagliflozin in improving insulin resistance in diabetic patients.

4. Use of the SNP molecular marker detection reagent according to claim 3 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The diabetes is type 2 diabetes.

5. Use of the SNP molecular marker detection reagent according to claim 4 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The molecular marker SNP site has three genotypes, namely homozygous CC, homozygous AA and heterozygous CA; The prediction is that the effect of dapagliflozin on improving insulin resistance is poorer in type 2 diabetes patients carrying the CC genotype of the molecular marker SNP site than in type 2 diabetes patients carrying the AA or CA genotype of the molecular marker SNP site.

6. Use of the SNP molecular marker detection reagent according to claim 2 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The product is a Snapshot SNP typing kit.

7. Use of the SNP molecular marker detection reagent according to claim 6 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The kit contains specific amplification primers and extension primers for the SNP molecular markers.

8. Use of the SNP molecular marker detection reagent according to claim 7 in the preparation of a product for predicting the efficacy of dapagliflozin, It is characterized in that The sequences of the specific amplification primer and the extension primer are shown in SEQ ID NOs. 2 to 4 respectively.

Citation Information

Patent Citations

  • Uses and method for polymorphic point genetype for predicting sulfaurea drugs effect

    CN101008032A

  • Diabetes-related biomarkers and methods of use thereof

    US20090012716A1